|Mr. Ryan D. Lake||Chief Financial Officer||572.13k||N/A||1977|
|Mr. J. David Enloe Jr.||Pres, CEO & Director||N/A||N/A||1964|
|Mr. William Hirschman||VP of Sales & Marketing||N/A||N/A||N/A|
|Mr. Randall J. Mack||Sr. VP of Devel.||N/A||N/A||1965|
|Mr. Marshall Rizzo M.B.A.||Sr. VP & Gen. Mang.||N/A||N/A||N/A|
|Mr. Richard Sidwell Ph.D.||VP & Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Carla Lusby||Corp. Sec.||N/A||N/A||N/A|
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.
Recro Pharma, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 9.